Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY).
Calcitonin gene-related peptide
Galcanezumab
Long-term treatment
Migraine
Migraine prevention
Monoclonal antibodies
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
21
10
2023
accepted:
15
01
2024
pubmed:
8
2
2024
medline:
8
2
2024
entrez:
8
2
2024
Statut:
ppublish
Résumé
Galcanezumab is approved in the European Union (EU) as migraine prophylaxis in adults with at least four migraine days per month. The aim of this retrospective observational study was to evaluate the long-term effectiveness of galcanezumab on migraine-related burdens and its impact on the use of healthcare resources for migraine prophylaxis in an Italian setting. This retrospective study was conducted in patients with migraine who initiated treatment with galcanezumab for migraine prevention between September 2019 and December 2020. Patient data for monthly migraine days (MMDs) and MMDs with acute medication intake were obtained by medical chart reviews. Information on patient-reported outcomes (using the Migraine Disability Assessment [MIDAS] questionnaire and Headache Impact Test 6 [HIT-6] questionnaire) and on the use of healthcare resources were also collected. The time points of interest were 1, 3, 6, 9, 12 months after the initiation of galcanezumab, and the most recent time point available during follow-up. A total of 207 patients were enrolled in the study. Starting from month 3 after treatment initiation, more than half of the patients presented at least a 50% reduction in MMDs, and approximately one-third of non-responders at month 3 became responders at month 6. From month 3 to month 12, MMDs decreased on average by 10 days. Headache impact and disability, as well as migraine-associated health resource utilization decreased significantly during the treatment period. A positive significant association among the three dimensions of clinical burden (MMDs, MIDAS and days of acute medication intake) was also observed. The results of this Italian real-world study confirmed that galcanezumab has a rapid onset of effect and provides a long-term response among patients over different migraine-related burdens. The use of healthcare resources was also remarkably reduced.
Sections du résumé
BACKGROUND
BACKGROUND
Galcanezumab is approved in the European Union (EU) as migraine prophylaxis in adults with at least four migraine days per month. The aim of this retrospective observational study was to evaluate the long-term effectiveness of galcanezumab on migraine-related burdens and its impact on the use of healthcare resources for migraine prophylaxis in an Italian setting.
METHODS
METHODS
This retrospective study was conducted in patients with migraine who initiated treatment with galcanezumab for migraine prevention between September 2019 and December 2020. Patient data for monthly migraine days (MMDs) and MMDs with acute medication intake were obtained by medical chart reviews. Information on patient-reported outcomes (using the Migraine Disability Assessment [MIDAS] questionnaire and Headache Impact Test 6 [HIT-6] questionnaire) and on the use of healthcare resources were also collected. The time points of interest were 1, 3, 6, 9, 12 months after the initiation of galcanezumab, and the most recent time point available during follow-up.
RESULTS
RESULTS
A total of 207 patients were enrolled in the study. Starting from month 3 after treatment initiation, more than half of the patients presented at least a 50% reduction in MMDs, and approximately one-third of non-responders at month 3 became responders at month 6. From month 3 to month 12, MMDs decreased on average by 10 days. Headache impact and disability, as well as migraine-associated health resource utilization decreased significantly during the treatment period. A positive significant association among the three dimensions of clinical burden (MMDs, MIDAS and days of acute medication intake) was also observed.
CONCLUSION
CONCLUSIONS
The results of this Italian real-world study confirmed that galcanezumab has a rapid onset of effect and provides a long-term response among patients over different migraine-related burdens. The use of healthcare resources was also remarkably reduced.
Identifiants
pubmed: 38329615
doi: 10.1007/s40120-024-00582-0
pii: 10.1007/s40120-024-00582-0
doi:
Types de publication
Journal Article
Langues
eng
Pagination
415-435Informations de copyright
© 2024. The Author(s).
Références
Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–15. https://doi.org/10.1016/j.jns.2016.11.071 .
doi: 10.1016/j.jns.2016.11.071
pubmed: 28017235
Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general practice. Aten Primaria. 2022;54(2):102208. https://doi.org/10.1016/j.aprim.2021.102208 .
doi: 10.1016/j.aprim.2021.102208
pubmed: 34798397
Doane MJ, Vo P, Bilitou A et al. Economic impact of migraine in the EU5: a matched analysis of the NHWS 2017 data on work productivity and healthcare resource use. Abstract no. [MTIS2018-083]. In: MTIS 2018 abstracts. Cephalalgia. 2018;38(1S). https://journals.sagepub.com/doi/pdf/10.1177/0333102418789865 .
Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–14. https://doi.org/10.1038/s41582-021-00509-5 .
doi: 10.1038/s41582-021-00509-5
pubmed: 34145431
pmcid: 8321897
Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients—a review of pros and cons. J Headache Pain. 2017;18:96. https://doi.org/10.1186/s10194-017-0807-1 .
doi: 10.1186/s10194-017-0807-1
pubmed: 28948500
pmcid: 5612904
European Medicines Agency. Emgality. 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/emgality . Accessed 13 Jan 2023.
Martin V, Samaan KH, Aurora S, et al. Efficacy and safety of galcanezumab for the preventive treatment of migraine: a narrative review. Adv Ther. 2020;37:2034–49. https://doi.org/10.1007/s12325-020-01319-9 .
doi: 10.1007/s12325-020-01319-9
pubmed: 32319039
pmcid: 7467458
Ruff DD, Ford JH, Tockhorn-Heidenreich A, et al. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. Eur J Neurol. 2020;27:609–18. https://doi.org/10.1111/ene.14114 .
doi: 10.1111/ene.14114
pubmed: 31692188
Mulleners WM, Kim B-K, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814–25. https://doi.org/10.1016/S1474-4422(20)30279-9 .
doi: 10.1016/S1474-4422(20)30279-9
pubmed: 32949542
Vernieri F, Brunelli N, Marcosano M, et al. Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: the multicenter prospective cohort GARLIT study. Eur J Neurol. 2023;30:224–34. https://doi.org/10.1111/ene.15563 .
doi: 10.1111/ene.15563
pubmed: 36097739
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211. https://doi.org/10.1177/0333102417738202 .
Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–8. https://doi.org/10.1001/jamaneurol.2018.1212 .
doi: 10.1001/jamaneurol.2018.1212
pubmed: 29813147
pmcid: 6143119
Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–54. https://doi.org/10.1177/0333102418779543 .
doi: 10.1177/0333102418779543
pubmed: 29848108
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–21. https://doi.org/10.1212/WNL.0000000000006640 .
doi: 10.1212/WNL.0000000000006640
pubmed: 30446596
pmcid: 6329331
Altamura C, Brunelli N, Marcosano M, et al. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022;269:5848–57. https://doi.org/10.1007/s00415-022-11226-4 .
doi: 10.1007/s00415-022-11226-4
pubmed: 35763113
pmcid: 9243974
Vernieri F, Altamura C, Brunelli N, et al. Rapid response to galcanezumab and predictive factors in chronic migraine patients: a 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol. 2022;29:1198–208. https://doi.org/10.1111/ene.15197 .
doi: 10.1111/ene.15197
pubmed: 34826192
Vernieri F, Altamura C, Brunelli N, et al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22:35. https://doi.org/10.1186/s10194-021-01247-1 .
doi: 10.1186/s10194-021-01247-1
pubmed: 33941080
pmcid: 8091153
Kwon S, Gil Y-E, Lee MJ. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia. 2022;42:705–14. https://doi.org/10.1177/03331024221076481 .
doi: 10.1177/03331024221076481
pubmed: 35301884
Schwedt TJ, Kuruppu DK, Dong Y, et al. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain. 2021;22:15. https://doi.org/10.1186/s10194-021-01230-w .
doi: 10.1186/s10194-021-01230-w
pubmed: 33765912
pmcid: 7992932
Barbanti P, Aurilia C, Egeo G, et al. Late response to Anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. Neurology. 2023;101(11):482-8. https://doi.org/10.1212/WNL.0000000000207292 .
Ambrosini A, Estemalik E, Pascual J, et al. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER). J Manag Care Spec Pharm. 2022;28:645–56. https://doi.org/10.18553/jmcp.2022.21375 .
doi: 10.18553/jmcp.2022.21375
pubmed: 35451858
Raffaelli B, Terhart M, Overeem LH, et al. Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. 2022;42:326–34. https://doi.org/10.1177/03331024211046617 .
doi: 10.1177/03331024211046617
pubmed: 34579559
Vernieri F, Brunelli N, Messina R, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021;22:154. https://doi.org/10.1186/s10194-021-01363-y .
doi: 10.1186/s10194-021-01363-y
pubmed: 34922444
pmcid: 8903705
Iannone LF, Fattori D, Benemei S, et al. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. 2022;29:1505–13. https://doi.org/10.1111/ene.15260 .
doi: 10.1111/ene.15260
pubmed: 35098620
Silvestro M, Tessitore A, Orologio I, et al. Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. J Headache Pain. 2022;23:69. https://doi.org/10.1186/s10194-022-01436-6 .
doi: 10.1186/s10194-022-01436-6
pubmed: 35698070
pmcid: 9195341
Barbanti P, Egeo G, Aurilia C, et al. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain. 2022;23:138. https://doi.org/10.1186/s10194-022-01498-6 .
doi: 10.1186/s10194-022-01498-6
pubmed: 36316648
pmcid: 9623966
Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U. A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals (Basel). 2023;16(7):934. https://doi.org/10.3390/ph16070934 .
doi: 10.3390/ph16070934
pubmed: 37513846
Raffaelli B, Fitzek M, Overeem LH, Storch E, Terhart M, Reuter U. Clinical evaluation of super-responders vs non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. J Headache Pain. 2023;24(1):16. https://doi.org/10.1186/s10194-023-01552-x .
doi: 10.1186/s10194-023-01552-x
pubmed: 36843007
pmcid: 9969617